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Abstract
While immunological memory has long been considered the province of T- and B- lymphocytes, it has recently been
reported that innate cell populations are capable of mediating memory responses. We now show that an innate memory
immune response is generated in mice following infection with vaccinia virus, a poxvirus for which no cognate germline-
encoded receptor has been identified. This immune response results in viral clearance in the absence of classical adaptive T
and B lymphocyte populations, and is mediated by a Thy1
+ subset of natural killer (NK) cells. We demonstrate that immune
protection against infection from a lethal dose of virus can be adoptively transferred with memory hepatic Thy1
+ NK cells
that were primed with live virus. Our results also indicate that, like classical immunological memory, stronger innate
memory responses form in response to priming with live virus than a highly attenuated vector. These results demonstrate
that a defined innate memory cell population alone can provide host protection against a lethal systemic infection through
viral clearance.
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Introduction
Immunological memory allows the immune system to provide
enhanced host protection upon secondary exposure to an
infectious pathogen. Memory has long been considered the sole
province of adaptive lymphocytes. Lymphocytes recognize path-
ogens via unique somatically-rearranged antigen receptors,
expand clonally upon activation, and eventually give rise to a
population of long-lived progeny. These progeny cells maintain
their antigenic specificity and exhibit enhanced functional activity
upon secondary exposure to a priming pathogen.
Recent studies have suggested that a reconsideration of the
classical paradigm of immunological memory is warranted. These
studies have shown that innate cell populations have the capacity to
generate enhanced responses upon secondary exposure to the
priming immunogen[1,2,3]. O’Leary, et al., demonstrated that NK
cell-mediated delayed-type hypersensitivity (DTH) responses[1] can
be generated upon secondary exposure to sensitizing compounds.
Further, they showed that these compound-specific DTH responses
were mediated by a liver-resident NK cell population expressing the
Thy1 (CD90) molecule. Recently, Sun, et al. demonstrated that an
innate memory response forms to MCMV and is mediated by a
population of NK cells expressing Ly49H. In mice containing the
B6 haplotype NK complex, NK cells expressing the germline-
encoded NK receptor Ly49H—an activating NK receptor
identified that is capable of specifically recognizing a virally-
encoded product (the MCMV protein m157)[4,5]—are the predo-
minant contributors to the innate response to a primary MCMV
infection[2,6,7,8,9,10,11]. Sun et al., made use of the cognate
recognition of m157 by Ly49H
+ to establish the specificity of the
enhanced host protection provided by memory Ly49H
+ NK cells
upon re-exposure to MCMV[2].
Recently, a report from the von Andrian laboratory [3] showed
that CXCR6
+ NK cells primed with virus-like particles (VLPs)
expressing viral transgenes were capable of mediating antigen-
specific contact hypersensitivity (CH) in response to antigens not
known to be recognized by germline-encoded receptors. These
memory NK cells were also capable of providing partial host
protection from infection with live virus expressing the priming
antigens, as measured by a delay in mortality upon lethal viral
challenge and the capacity to resolve localized, lower dose viral
infection. Further, they demonstrated that signaling through
CXCR6, a chemokine receptor that binds to CXCL16 (primarily
expressed by hepatic sinusoidal epithelium), is critical for the
maintenance of this hepatic NK memory population of cells.
The present studies were initiated to determine whether innate
memory could contribute to the control of viral pathogens for
which no cognate germline-encoded receptor has been identified.
Furthermore, we wanted to assess whether innate memory cells
alone can provide protection against a viral challenge in the
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experiments, we used live vaccinia virus to prime and challenge
the memory NK cell population and demonstrate that memory
NK cells alone are capable of providing sterilizing protection
against a systemic challenge with a fatal dose of the priming
pathogen. This protection was mediated by a Thy1
+ subset of
hepatic NK cells primed with live vaccinia virus; hepatic Thy1
+
NK cells primed with a highly attenuated strain of vaccinia
(Modified Vaccinia Ankara (MVA)) were unable to confer this
protection upon adoptive transfer into naı ¨ve, immunodeficient
hosts. This suggests that innate memory, like classical adaptive
memory, is primed more efficiently with live, replication-
competent organisms. We demonstrate that innate memory to
vaccinia virus is extremely durable, as the memory NK cells that
mediated clearance of the lethal pathogen were active greater than
6 months after priming with the live pathogen. We also show that
on a cellular level, enhanced activation of hepatic NK cells from
virally primed mice can be demonstrated not just in response to
the pathogen, but in response to more generalized stimuli.
Results
We chose vaccinia virus (VV) as a pathogen for these studies
because immunocompetent mice resolve vaccinia virus infection
through a combination of humoral and cell-mediated adaptive
immune responses[12]. Moreover, the virus is highly pathogenic in
naı ¨ve mice that lack classical adaptive immune function. By
infecting mice with a recombinant vaccinia virus expressing the
transgene firefly luciferase (rVV-luc), we were able to monitor the
infection in vivo by periodically injecting luciferin-D (the luminescent
substrate for firefly luciferase) into the mice and using the IVIS
imaging system to monitor viral burdens and virus localization.
First, we infected mice in which the IgHm constant region has
been disrupted (the mMT mouse; IgH
ko)[13] which results in a
consequent failure to develop mature B cells. The genetic block in
B cell development is extremely stringent when in C57Bl/6 (B6)
mice[13,14] (data not shown). We used the IgH
ko B6 mice for
these studies to eliminate the possibility that a humoral immune
response might develop during a primary infection with vaccinia
virus that could confer protection against a secondary exposure to
virus. We also reasoned that T lymphocytes present in these mice
would clear a primary vaccinia virus infection efficiently; RAG1
ko
mice (mice that lack both T and B cells) succumb to primary
infection with vaccinia virus at very low doses. In using the IgH
ko
B6 mouse model, we could prime mice in the presence of T cells,
thereby allowing the IgH
ko mice to survive the primary infection,
and then eliminate cell subpopulations in vivo by administration of
monoclonal antibodies prior to secondary challenge. Antibody-
mediated depletion of T cells could be maintained indefinitely in
the IgH
ko mice by repeated administration of depleting antibodies
since these mice cannot generate anti-Ig antibody responses that
might interfere with the infused antibodies.
A non-T-, non-B- lymphocyte population provides host
protection upon secondary exposure to vaccinia virus
IgH
ko mice received an inoculation of either PBS (control naı ¨ve
IgH
ko), or 1610
7 plaque forming units (pfu) of rVV-luc
intraperitoneally (ip) (primed IgH
ko)). We then rested the mice
for a minimum of six months after clearance of the rVV-luc (as
determined by IVIS imaging; Fig. S1) to ensure that any effects
we observed during a secondary challenge would reflect the
influence of a durable, long-lived memory immune response rather
than the activity of residual effector cell populations that may have
persisted following clearance of the virus. Ten days prior to a
secondary vaccinia virus challenge we began administering isotype
control antibodies or a cocktail of T cell- depleting monoclonal
antibodies (clones GK1.5 (aCD4)[15], H57–597 (aTCRß)[16],
and UC7-13D5 (aTCRcd)[17]) ip to groups of naı ¨ve and primed
animals. We did not include a CD8a-depleting monoclonal
antibody in this cocktail because we did not want the depletion of
CD8a
+ innate populations of cells to potentially confound the
outcome of the experiments. The monoclonal antibody mixtures
were administered every two weeks throughout the life of the
experiment to maintain T cell depletion. The efficiency of T cell
depletion was monitored by flow cytometric analysis of peripheral
blood stained with a panel of monoclonal antibodies, including
antibodies specific for CD3, TCRb, TCRcd, and NK1.1.
Representative flow cytometry plots from control and T cell-
depleted mice 1 week post-challenge showed that the efficiency of
T cell depletion was extremely high, greater than 99% as
measured by percentage of CD3
+ within the lymphocyte gate
(Fig. 1a). Very few of those cells that fall within the CD3
+ gate in
the depleted mice showed staining for TCRb, TCRcd, or CD8a;
there are no masking antibodies to CD3 or CD8a present in the
cocktail. Moreover, pilot studies performed in control B6 mice
showed that the extent of T cell depletion in the peripheral blood
following administration of the depleting antibodies reflected the T
cell depletion in spleen and lymph nodes (data not shown).
In repeated experiments, we observed that both primed (data
not shown) and naı ¨ve IgH
ko mice treated with isotype control
antibodies were capable of clearing vaccinia virus infection.
However, in the T cell-depleted groups of mice, only the primed
mice (primed, T-depleted IgH
ko) were capable of resolving the
infection (Fig 1, b and c). Representative IVIS images show the
kinetics of vaccinia virus clearance in each of the groups of mice
(Fig. 1b). The luminescence measurements on all mice demon-
strated that while naı ¨ve, T-depleted IgH
ko were incapable of
controlling vaccinia virus after challenge, the primed T-depleted
IgH
ko mice resolved the infection (Fig. 1c). The clearance of
vaccinia virus infection occurred within 2–3 weeks in primed, T
cell-depleted mice (Fig. 1, b and c), more slowly than virus
clearance occurred in primed, control IgH
ko mice (clearance in 1
week-data not shown) or in naı ¨ve, control IgH
ko mice (clearance in
Author Summary
Immunological memory is a hallmark of adaptive immunity
and provides the basis for our ability to become ‘immune’
to pathogens to which we have previously been exposed,
and provides the basis for vaccination. For decades, the
paradigm held that only the classical adaptive lympho-
cytes were capable of forming and maintaining protective
immunological memory. Recently, several papers have
shown the capacity of an innate cell population, a subset
of natural killer (NK) cells, to exhibit certain aspects of
immunological memory. Here we show that innate
memory forms in response to infection with vaccinia virus
and resides in a discrete subset of NK cells. We further
demonstrate that this innate memory provides significant
host protection against a subsequent systemic infection
with a lethal dose of vaccinia virus, in some cases resulting
in the complete clearance of detectable virus. We also
demonstrate that priming with live, replicating virus
stimulates innate memory more robustly than a highly
attenuated vector. These findings shed new light on this
emergent area of immunology, and hold significant
implications for harnessing innate memory as part of
creating novel vaccination strategies.
Innate Memory Provides Protection against Vaccinia
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mice had resolved the vaccinia virus infection, there was no
evidence of a later recrudescence of viral replication. In mice that
succumbed to vaccinia (naı ¨ve, T cell-depleted IgH
ko), we observed
spread of vaccinia virus from the peritoneal cavity into hotspots
located on the tails, feet, and mouths of infected mice. This
distribution of vaccinia virus was consistent with previous
reports[12] and was likely the result of transfer of infection to
satellite sites via saliva. Together, these data suggest that the long-
term resolution of vaccinia virus infections can occur in the
absence of classical adaptive immune effector mechanisms.
Thy1 (CD90) expression identifies the non-T, non-B cell
population that provides protection upon secondary
exposure to vaccinia virus
We next sought to identify the cell population(s) that mediated
this non-T and non-B cell protective memory response in vivo.
Since Thy1
+ lymphokine-activated killer (LAK) cells have been
implicated in protection against infection with vaccinia vi-
rus[18,19,20,21,22], and O’Leary, et al., have shown that the
multiple compound-specific DTH responses they observed are
mediated by a liver-resident Thy1
+ NK cell population[1], we
hypothesized that Thy1
+ NK cells may be the effector population
providing protection against secondary vaccinia virus infection. To
explore this possibility, we inoculated groups of IgH
ko mice with
either 1610
7 pfu rVVluc (primed IgH
ko) or PBS (naı ¨ve IgH
ko) ip.
Eight months later, these mice were treated either with isotype
control antibodies, the T cell-depleting antibody cocktail (300 mg
each of clones GK1.5, H57–597, and UC7-13D5), or a T- and
Thy1-depleting antibody cocktail (300 mg each of clones GK1.5,
H57–597, UC7-13D5, and the Thy1.2 (CD90.2)-specific clone
30H12[23]); the monoclonal antibody mixtures were administered
every 2 weeks throughout the course of the experiment to maintain
T and Thy1
+ cell depletion. One week after initiating monoclonal
antibody administration, all groups of mice were challenged ip
Figure 1. A primed innate cell population provides protection against a challenge with recombinant vaccinia virus. Six months after
intraperitoneal (ip) inoculation with vaccinia virus (primed) or PBS (naı ¨ve), IgH
ko mice were treated with T cell-depleting or isotype control antibody
mixtures and 10 days later were challenged with 2610
6 pfu rVV-luc intraperitoneally (ip). Isotype control or depleting monoclonal antibodies were
administered ip every 2 weeks starting a week to ten days prior to viral challenge. (a) Flow cytometric plots of CD3 staining of peripheral blood cells
from naı ¨ve control, naı ¨ve T-depleted, or primed T-depleted mice that fall within the lymphocyte gate are shown, including the percentage of total
cells within the CD3
+ gate at 1 week post-challenge. The TCRb, TCRcd, and CD8a staining profiles of the cells that fall within the CD3
+ gate are also
shown. (b) IVIS images of representative mice from the naı ¨ve control, naı ¨ve T cell-depleted, and primed T cell-depleted groups following the
challenge with rVV-luc are shown. (c) The measurements of rVV-luc viral loads in each group over time are shown with relative viral loads based on
the number of photons emitted normalized for a one minute exposure. The measurement for each individual mouse is plotted, and the center line
indicates the mean with error bars representing the SEM. Statistical significance between T-depleted groups was assessed by t-tests using Mann-
Whitney analysis and is indicated by the asterisk (p,0.05). Results are representative of 4 independent experiments.
doi:10.1371/journal.ppat.1002141.g001
Innate Memory Provides Protection against Vaccinia
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6 pfu rVV-luc. Representative flow cytometric plots of
peripheral blood cells from groups of naı ¨ve and primed mice 2
weeks after challenge demonstrate that the depletion of the target
cell populations by monoclonal antibody administration was
extremely efficient (.99% T cell depletion in all groups at 2
weeks post-challenge; Fig. 2a). Depletion of T cells had no
significant impact on the number of NK cells present in the
peripheral blood. We did observe a significant shift in the
representation of Thy1 (CD90)
+ NK cells in mice that had been
depleted of T cells. Nevertheless, the proportion of Thy1
+ NK cells
was comparable in the naı ¨ve and primed groups (Fig. 2b),
suggesting that differences in clearance and survival between the
naı ¨ve and primed T-depleted groups is not a consequence of
differential effects of T cell depletion on the NK cell populations.
As anticipated, the addition of the Thy1.2 (CD90.2)-depleting
monoclonal antibody 30H12 in the T&Thy1-depleting cocktail
efficiently eliminated all Thy1
+ NK cells in IgH
ko recipients
(Fig. 2b). Both the naı ¨ve and primed IgH
ko control (T cell-
competent) groups of mice cleared the infection with kinetics
consistent with primary (naı ¨ve IgH
ko) and secondary (primed
IgH
ko) adaptive immune responses, respectively (Fig. 2, c and d).
As observed in the initial series of experiments, the naı ¨ve, T-cell-
depleted IgH
ko mice were unable to control the challenge infection
while the primed, T cell-depleted IgH
ko mice resolved the vaccinia
virus infection within 2–3 weeks. However, depletion of both T
cells and Thy1
+ non-T cells abrogated the protection that was
evident in the primed T-cell-depleted IgH
ko group (Fig. 2c and
d). The naı ¨ve T- and Thy1-depleted mice also succumbed to
infection. These data suggested that the cell population(s)
mediating protection against secondary vaccinia virus challenge
was a Thy1
+, non-T, non-B cell population.
To examine the comparability of data generated using the
luciferase/IVIS system and data generated using a traditional
strategy for measuring vaccinia virus infection in vivo, we quantified
vaccinia virus titers in ovaries of primed T-depleted and primed T-
and Thy1-depleted groups of mice. The results established that the
clearance of luciferase activity in primed T-depleted animals as
visualized using the IVIS technology correlated with an inability to
detect vaccinia virus in ovaries of these animals (Fig. S2 and data
not shown). This observation indicates that viral clearance as
measured by IVIS is consistent with traditional methods of
measuring viral clearance.
NK cells from pathogen-primed mice retain enhanced
effector capacity long after clearance
One of the fundamental characteristics of a classical memory
response is that memory cells exhibit enhanced activation upon
secondary stimulation. Therefore, we wanted to determine if
functional differences existed between NK cells from naı ¨ve and
vaccinia virus-primed mice. To do so, we performed in vitro
activation assays using isolated liver mononuclear cell prepara-
tions. We pooled liver mononuclear cells from groups of 8–12
age-matched naı ¨ve mice and mice that had been VV-primed 6
months earlier to ensure that we could isolate sufficient numbers of
cells for stimulation and analysis. These cell preparations were
isolated from enzymatically-dissociated livers via percoll gradient
separation and 5610
5 cells/well were aliquoted into 24 well plates.
The cells were then incubated for 6 hours in the presence of
fluorescently-labeled anti-CD107a/b antibodies in wells contain-
ing either no stimulus, PMA and ionomycin, 200 micrograms of
plate-bound isotype control antibody (clone CI.8), 200 micrograms
of plate-bound anti-NK1.1 antibody (clone PK-136), or either
2610
6 pfu of vaccinia virus or 2610
6 viral particles (vp) of
recombinant adenovirus that had been treated with 2% parafor-
maldehyde. The recovered cells were washed, stained for CD69
expression, and fixed prior to flow cytometric analysis. In each
condition, analysis on gated NK cells (NK1.1
+CD3
2) showed that
the NK cells from vaccinia virus-primed animals showed higher
activation, as determined by CD69 (activation) and CD107a/b
(degranulation) staining (Fig. 3). Primed NK cells showed
significantly higher levels of activation and degranulation than
naı ¨ve NK cells when stimulated with PMA and ionomycin (24.1%
CD69
+CD107
+ for primed NK vs. 14.3% for unprimed; specific
activation above unstimulated 13.5% for primed vs. 7.1% for
unprimed NK), and plate-bound anti-NK1.1 antibody (40.8%
primed vs. 22.1% unprimed; specific activation above isotype-
stimulated 29.3% primed vs. 14.3% unprimed). This activation
occurred in response to the indicated stimuli, as activation was well
above control levels, and by stimuli that were not dependent on a
presenting cell population or the presence of vaccinia virus
antigens. The cells also showed an enhanced response to fixed,
plate-bound vaccinia virus when compared to the unstimulated
control cells (16.5% primed vs. 9.9% unprimed; specific activation
above unstimulated 5.9% primed vs. 2.7% unprimed), although
the response to vaccinia virus was only marginally higher than the
response to an unrelated virus (16.5% primed vs. 9.9% unprimed
responded to vaccinia virus, while responses to adenovirus were
14.2% primed vs. 8.6 unprimed; vaccinia-induced activation
relative to adenovirus-induced activation 2.3% primed vs. 1.3%
unprimed). These results showed that, as with the non-specific
stimuli, primed NK cells exhibited significantly enhanced
activation relative to unprimed NK cells in response to direct
exposure to viral particles. However, the relatively small increases
in activation seen in both primed and unprimed cells in response
to vaccinia virus as compared to an unrelated virus (adenovirus)
suggest that direct and specific recognition of vaccinia virus
antigens plays a limited role in stimulating both vaccinia –primed
and –unprimed NK cells. Collectively, these results show that NK
cells from vaccinia virus-primed mice were more responsive than
NK cells from naı ¨ve mice to a wide range of activating stimuli.
A Thy1
+ subset of NK cells dominates the NK response
during primary infection with vaccinia virus
We next characterized the dynamics of NK cell populations
throughout the course of vaccinia virus infection in unmanipulat-
ed, wild type mice. B6 mice were administered PBS (control) or
1610
7 pfu of rVV (challenged) ip. At various time points after
infection, groups of control and challenged mice were sacrificed,
and cells from the peripheral blood, spleen, and liver were isolated,
counted, and analyzed by monoclonal antibody staining and flow
cytometry. A rapid expansion was seen in the absolute number of
NK cells in the spleen (data not shown) and liver (Fig. 4a) during
the first week following challenge, followed by a contraction of this
population as the infection resolved. By 7 days following infection,
the absolute number of liver NK cells (CD3
2NK1.1
+) had
increased 5-fold. There was a preferential expansion of the
Thy1
+ NK cell population in the liver of infected mice, with the
representation of Thy1
+ cells increasing in the liver both as a
percentage of total NK cells (from 46% to 64% of total liver NK
cells by day 4 post-challenge) and in their absolute number (a 10-
fold increase over baseline by 7 days after infection). A preferential
expansion of splenic Thy1
+ NK cells was also observed, albeit to a
lesser degree (approximately 2–fold expansion in the total number
of splenic NK cells, and a 5-fold expansion in the number of
Thy1
+ splenic NK cells; the percentage of total splenic NK cells
that were Thy1
+ rose from a baseline of 32% to a peak of 57% by
4 days post-infection; data not shown).
Innate Memory Provides Protection against Vaccinia
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NK cells following vaccinia virus infection. These cells were
stained with antibodies specific for NK-associated cell surface
molecules, including CD94, NKG2D, CD43, Ly49H, Ly6C,
KLRG1, CD27, CD11b, and Thy1 (Fig. 4, b and c). During the
first week after vaccinia virus challenge, the absolute number of all
NK subsets we analyzed had increased. However, we were able to
identify several NK cell subsets that preferentially increased in
number and percentage: the total Thy1
+ NK cell population, as
described above, and a subpopulation of Thy1
+ NK cells that were
also KLRG1
hi. Most of these cells were phenotypically
NKG2D
brightLy6C
hiCD27
loCD11b
hiCD43
hi (Fig. 4, b and c,
and data not shown). The representation of this KLRG1
hi
population rose from approximately 5% to a peak of 20–25% of
the liver Thy1
+ NK cell population by days 4–7 after infection,
and then contracted to baseline levels by 21 days after challenge
(Fig. 4b and c). However, by 118 days after challenge there were
no phenotypically discrete subsets within the Thy1
+ NK cell subset
that we could identify as potential memory populations.
Expansion of NK cells in liver results from in situ
proliferation
We wanted to determine whether the expansion of Thy1
+ NK
cells observed in the liver and spleen during primary infection
were a consequence of proliferation or an alteration in NK cell
trafficking. Groups of B6 mice were infected with 1610
7 pfu rVV
ip , and at various time points administered the thymidine
analogue ethynyl deoxyuridine (EdU) 12 hours prior to sacrifice.
We designed the experiment to allow the assessment of the
proliferative activity within the NK cell population at various time
points rather than following continuous EdU administration. As
shown in Fig. 5, extensive proliferation within the NK cell
Figure 2. A Thy1
+ cell population mediates innate protection against a secondary challenge with vaccinia virus. Eight months after the
initial administration of vaccinia virus (primed) or PBS (naı ¨ve), IgH
ko mice were treated with either isotype control or depleting monoclonal antibodies,
then challenged ten days later with 2610
6 pfu rVV-luc. Isotype control and depleting monoclonal antibodies were administered ip every 2 weeks
beginning one week to ten days prior to viral challenge. (a) Representative flow cytometric plots of staining of all cells that fall within the CD3
+ and
CD3
2 lymphocyte gates from peripheral blood 2 weeks after the secondary challenge are shown. (b) Histograms of CD90.2 expression by the NK cell
population (gated on CD3
2NK1.1
+ cells) isolated from peripheral blood of each of the indicated groups are shown. (c) IVIS images of representative
IgH
ko mice from naı ¨ve isotype control, naı ¨ve and primed T cell-depleted, and naı ¨ve and primed T- and Thy1(CD90.2)
+- cell depleted groups are shown
at various time points following secondary challenge with rVV-luc. (d) The measurements of rVV-luc viral loads in each group over time are shown,
with relative viral loads based on the number of photons emitted normalized for a one minute exposure. The measurement for each individual
mouse is plotted, and the mean is indicated by the centerline with error bars representing the SEM. Statistical significance between T-depleted and
T&Thy1-depleted groups was assessed by t-tests using Mann-Whitney analysis and is indicated by the asterisk (p,0.05). Results are representative of
4 independent experiments.
doi:10.1371/journal.ppat.1002141.g002
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stimulation. Lymphocytes and NK cells isolated from collagenase-dissociated liver preparations from naı ¨ve and vaccinia virus-infected mice were
cultured in vitro with the indicated stimuli for 6 hours prior to evaluation for NK cell activation (expression of CD69) and degranulation (expression
of CD107) in response to the stimulation. Stimuli include plate-bound isotype control Ig, the anti-NK1.1 monoclonal antibody PK-136,
formaldehyde-fixed adenovirus (2610
6 vp), and formaldehyde-fixed vaccinia virus (2610
6 pfu). Plots shown are gated on NK cells (NK1.1
+CD3
2 or
DX5
+CD3
2).
doi:10.1371/journal.ppat.1002141.g003
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preferential expansion of a Thy1
+ population. Mice were administered either PBS (control) or 1610
7 pfu of rVV (challenged) ip. At various time
points following challenge, cells were isolated from the enzymatically-dissociated livers of control and challenged mice. (a) The absolute number of
NK cells (CD3
2NK1.1
+), the absolute number of Thy1
+ NK cells (CD3
2 NK1.1
+ Thy1
+), and the percentage of total NK cells that were Thy1
+ are shown.
Each data point represents an individual mouse, with the mean indicated by the horizontal bar and error bars representing the SEM. Absolute liver NK
cell numbers were calculated by multiplying the total number of viable cells within the lymphocyte gate of each sample (as determined by analysis
on a Guava easyCyte instrument) by the percentage of those cells determined to be CD3
2NK1.1
+ by flow cytometric analysis. The representation of
Thy1
+ cells within the total NK cell population, both as a percentage and an absolute number, was also determined based on flow cytometric analysis
and the cell counts obtained by Guava analysis. Statistical analyses were performed using t tests and Mann-Whitney analysis comparing the various
time points to that of the naı ¨ve control group. Statistically significant differences between virally-infected groups post-challenge and the uninfected
control group are indicated by one (p,0.05) or two (p,0.01) asterisks. (b) Further phenotypic characterization of Thy1
+ liver NK cells following
vaccinia virus infection is shown in a series of histograms. The red traces represent cells from challenged mice and the blue traces represent cells from
control mice isolated at the same time point and stained with the same antibody cocktail. (c) Quantitative analyses of the phenotypic profiles of
Thy1(CD90)
+ NK cells (cells within the CD3
2NK1.1
+CD90.2
+ gate) stained with antibodies to the indicated molecules as determined by flow
Innate Memory Provides Protection against Vaccinia
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proliferating between days 3–4 post-challenge), and returned to
baseline levels by 7 days post-challenge (Fig. 5a). The preferential
expansion of Thy1
+ NK cells was seen at both day 4 and 7 post-
challenge (where the percentage of EdU
+ NK cells that were also
Thy1
+ reached levels of 74.6% and 82.9% respectively, compared
to 49% in naı ¨ve controls; Fig. 5b). These results are consistent
with the population dynamics observed in the liver NK cell
population (Fig. 4a), and suggest that the large increases in NK
cell number and Thy1
+ NK cell percentage in liver are driven by
in situ proliferation early in infection. In support of the mechanism
of in situ proliferation, plaque assays performed on de novo infected
animals showed that low levels of vaccinia virus could be recovered
from the livers of animals receiving vaccinia virus ip beginning at
4 hours post-infection and through day 4 post-infection (ranging
from 4610
2–5610
4 pfu; data not shown). This finding established
that pathogen is also present in situ and might directly stimulate the
expansion of Thy1
+ NK cells.
Adoptive transfer of vaccinia-primed hepatic Thy1
+ NK
cells confers protection on naı ¨ve immunodeficient hosts
Our initial experiments in the IgH
ko model system indicated
that a VV-primed Thy1
+, non-T- non B- cell population was
capable of providing host protection upon secondary exposure to
the virus. However, despite the extreme efficiency of depletion
(.99%; Fig. 1a and Fig. 2, and b) achieved in the IgH
ko system,
in vivo depletion via monoclonal antibody administration was not
100% efficient. Therefore, it remained a formal possibility that the
protection we observed might be mediated by residual T cells. To
address the possibility of residual T cell contamination, and
cytometric analysis. Statistical analyses were performed using t tests and Mann-Whitney analysis comparing the various time points to that of the
naı ¨ve control group. Statistically significant differences between virally-infected groups post-challenge and the uninfected control group are
indicated by one (p,0.05) or two (p,0.01) asterisks.
doi:10.1371/journal.ppat.1002141.g004
Figure 5. Expansion of the NK cell population post-challenge is driven by proliferation in situ. Groups of B6 mice were either infected
with 1610
7 pfu rVV ip or given a control injection of PBS. The thymidine analog 5-ethynyl-29-deoxyuridine (EdU) was administered ip 12 hours prior
to sacrifice (250 mg EdU/animal). Cell suspensions isolated from liver were stained with monoclonal antibodies to CD3, NK1.1, and Thy1 (CD90.2),
fixed, permeabilized, and treated with the Click-IT EdU staining buffer with Alexa 647 azide to detect EdU incorporation. (a) The percentage of liver NK
cells (CD3
2NK1.1
+) that incorporated EdU is plotted over time. Statistical analyses were performed using t tests and Mann-Whitney analysis
comparing the various time points to that of the naı ¨ve control group. Statistically significant differences between virally-infected groups post-
challenge and the uninfected control group are indicated by one (p,0.05) or two (p,0.01) asterisks. (b) The percentage of EdU
+ liver NK cells
expressing Thy1 (CD90.2) is plotted over time. Statistical analyses were performed using t tests and Mann-Whitney analysis comparing the various
time points to that of the naı ¨ve control group. Statistically significant differences between virally-infected groups post-challenge and the uninfected
control group are indicated by one (p,0.05) or two (p,0.01) asterisks. (c) Representative histograms measuring EdU incorporation by total liver NK
cells is shown in the top panel, while representative histograms measuring Thy1 (CD90.2) expression by cells within the corresponding EdU
+ gate are
represented in the lower panel. These results are representative of two independent experimental replicates.
doi:10.1371/journal.ppat.1002141.g005
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+ NK cells could confer
protection against vaccinia virus, we evaluated the anti-viral
activity of these cells in an adoptive transfer system. First, we
wanted to establish that any protection we might observe in mice
receiving these transferred cells was mediated by the transferred
NK cell populations and not by contaminating T cells. To
determine if we could adequately control for contaminating T
lymphocytes in the transfers, we isolated NK cell-depleted liver
mononuclear cell preparations from enzymatically-dissociated
livers of naı ¨ve and vaccinia virus-primed mice by percoll gradient
separation followed by magnetic separation of non-NK cells. We
then transferred 2610
6 of these NK-depleted mononuclear cells (a
mixture of T cells, B cells, macrophages, DCs, and granulocytes)
into naı ¨ve RAG1
ko mice; one group received naı ¨ve NK-depleted
cells, one group received VV-primed non-NK cells, and a third
group received VV-primed non-NK cells in conjunction with the
administration of the T cell-depleting monoclonal antibody
cocktail utilized in the IgH
ko depletion experiments described
above. Five days after the transfer of these cells, we challenged the
recipients with 1610
5 pfu of rVV-luc ip and monitored their
ability to control infection using the IVIS system. Mice that
received naı ¨ve or VV-primed NK-depleted cells cleared the
infection with kinetics consistent with a primary (naı ¨ve recipients)
or secondary (primed recipients) T cell response (Fig. 6).
However, the mice that received the T cell-depleting monoclonal
antibody with the VV-primed non-NK cells were unable to
control infection and had to be sacrificed at d34 post-challenge.
These results indicate that even when transferring large numbers
of primed T lymphocytes into naı ¨ve RAG1
ko hosts, administration
of the T cell-depleting monoclonal antibody cocktail abrogated the
protection afforded by the transferred cells.
We then isolated NK cells from the collagenase-treated livers of
B6 or B6 congenic mice a minimum of 6 months after these mice
had received either PBS (naı ¨ve) or 1610
7 pfu rVVluc (primed) ip.
We utilized two congenic mouse models in these studies; B6.PL
mice, which express the CD90.1 isoform of CD90, or B6.SJL
mice, which express the CD45.1 isoform of CD45. The B6, IgH
ko,
and RAG
ko mouse models utilized in these studies express CD90.2
and CD45.2. Blood mononuclear cells were isolated from livers
after enzymatic digestion followed by Percoll gradient centrifuga-
tion, and NK cells were isolated from this cell fraction using the
MACS NK cell isolation kit and autoMACS instrument. Purified
NK cells were then separated into Thy1
2 and Thy1
+ populations.
Three distinct cell fractions were adoptively transferred into naı ¨ve
RAG1
ko mice: 5610
6 NK-depleted cells (a mixture of T cells, B
cells, macrophages, DCs, and granulocytes), 1610
5 Thy1
2 NK
cells, and 1610
5 Thy1
+ NK cells. The groups of mice receiving the
NK cell populations were treated with the T cell-depleting
monoclonal antibody cocktail at the time of transfer to ensure that
any contaminating T cells were eliminated. Thy1
+ NK cells, but
not T cells could be detected in the spleen or peripheral blood of
RAG1
ko hosts that received purified liver Thy1
+ NK cell transfers
4 weeks after transfer and challenge (Fig. S3); as expected, donor
T cells were readily apparent in the peripheral blood of mice
receiving NK-depleted liver cell transfers (Fig. S3), but were not
detectable in mice receiving NK cell transfers.
Five days after cell transfers (and concurrent T cell-depleting
antibody administration for recipients of purified NK cell
population transfers), we challenged these RAG1
ko mice with
1610
5 pfu rVV-luc ip and monitored the mice for viral burdens
using the IVIS system. Representative IVIS images of individual
mice from each of the experimental groups are shown in Fig. 7a,
and the persistence or clearance of virus in each mouse from each
group in 4 separate experiments are summarized in Fig. 7, b and
c. As predicted, the RAG1
ko mice that received naı ¨ve, NK cell-
depleted liver lymphocytes (15/16 mice; 94%) resolved the
vaccinia virus challenge within 2 weeks, and the RAG1
ko mice
that received the VV-primed NK cell-depleted liver lymphocytes
(15/15; 100%) resolved the vaccinia virus challenge within 1 week
(Figs. 7b and c, and data not shown). However, the groups of
RAG1
ko mice that received naive Thy1
2 (1/16; 6.25%) or Thy1
+
(0/17; 0%) NK cell populations, or VV-primed Thy1
2 (0/16; 0%)
NK cells were unable to resolve vaccinia virus infections.
Strikingly, a significant proportion of RAG1
ko mice that received
VV-primed Thy1
+ NK cell transfers (9/22; 41%) were able to
clear the challenge vaccinia virus infection by three weeks after
challenge, with viral clearance provided by transferred VV-primed
Thy1
+ NK cells significantly enhanced over mice receiving VV-
primed Thy1
2 NK cells (two-tailed t-test; p,0.01), naı ¨ve
Thy1
2NK cells (p,0.05), and naı ¨ve Thy1
+ NK cells (p,0.01)
transfers (Fig. 7b and c). Survival in these groups mirrored the
clearance we observed by IVIS (Fig. 7d). All mice that received
NK cell-depleted cells in transfer (cells that contained T
lymphocytes) survived; however, of NK cell transfer recipients,
only those that received the VV-primed Thy1
+ NK cells were
afforded significant protection, as shown by a survival rate of
greater than 40% (9/22 recipients). We also wanted to determine
if a highly attenuated poxvirus strain, MVA, was as capable of
priming for protective NK cell memory as replication competent
VV (Western Reserve strain). We transferred 1x10
5 Thy1
2 or
Thy1
+ NK cells isolated from the livers of naı ¨ve or MVA-primed
RAG1
ko mice into naı ¨ve RAG1
ko recipients, then challenged the
recipients with 1610
5 pfu rVV-luc IP 5 days after NK transfer. As
shown in Fig. 7e, no significant protection against a replication-
competent VV was observed in any of the recipients. These data
indicate that VV-primed, but not MVA-primed, Thy1
+ NK cells
can clear a lethal systemic challenge with VV.
To verify that the protection observed in these studies is
afforded by the transferred Thy1 (CD90)
+ NK cells and not
contaminating T lymphocytes, we isolated either NK-depleted
liver lymphocytes (2610
6/transfer) or liver Thy1
+NK cells
(1610
5/transfer) from B6.SJL (CD45.1
+CD90.2
+) mice and
transferred them into naı ¨ve RAG1
KO mice (CD45.2
+CD90.2
+)
with simultaneous administration of the T depleting monoclonal
antibody cocktail to the mice receiving the transferred NK cells.
Five days after transfer, recipients were infected with 1610
5 pfu
rVV-luc ip The course of the vaccinia virus infection in these
animals is indicated by both IVIS images and classical pfu assay
(Fig. 8). We were able to establish that the control (d7 post-
challenge; Fig. 8a) and resolution (d14 post-challenge; Fig. 8b)o f
challenge vaccinia virus infection observed in animals receiving
primed B6.SJL Thy1
+ (CD45.1
+CD90.2
+) NK cell transfers
occurred in the absence of contaminating T cells (CD45.1
+CD3
+)
and in the presence of the transferred Thy1
+ NK cells
(CD3
2NK1.1
+CD45.1
+CD90
+). The protection and clearance of
virus mediated in vivo by adoptively transferred B6.SJL NK-
depleted liver lymphocytes (including T cells;
CD3
+CD45.1
+CD90.2
+) at d14 post-challenge is also shown
(Fig. 8b). These results indicate that the protection observed
against vaccinia virus challenges in recipients of primed Thy1
+ NK
cells is mediated by the transferred NK cells and is not a
consequence of contaminating T lymphocytes in the transferred
cells.
Discussion
In these studies, we show that innate memory develops in
response to a viral infection in the absence of an identified cognate
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in primed, T-depleted IgH
ko mice was apparent by 4 days post-
challenge, indicating that the innate responses were both potent
and rapid. That we observed this innate protection in animals that
had resolved primary infection greater than 6 months prior to the
secondary challenge has two important implications. First, it
suggests that the protection represents a ‘memory’ response, rather
than the persistence of a residual population of activated effectors.
Second, the innate memory that formed following exposure to
vaccinia virus is extremely durable. We further established that the
complete protection we observed in the primed, T- depleted IgH
ko
mice was abrogated with the addition of the Thy1-depleting
antibody to the T cell depletion cocktail, indicating that innate
memory to vaccinia virus resides within a Thy1
+ non-T and non-B
cell population. Perhaps the most striking result we observed in
these experiments was that the memory provided by this innate
Thy1
+ cell population was manifested not only in enhanced
control of vaccinia virus infection during the early stages of
infection, but proved to be sufficiently potent to protect the
infected hosts against a systemic lethal dose of virus in the absence
of classical adaptive immune cells.
We performed experiments to determine if the memory Thy1
+
NK cell that responded to vaccinia virus had a unique, persistent
phenotype. In vitro stimulation assays established that the NK cells
from primed animals responded more vigorously than NK cells
from naı ¨ve animals, with increased CD69 upregulation and
degranulation upon exposure to both priming antigens (plate-
bound vaccinia virus) and a non- antigen-specific stimulus (plate-
bound anti-NK1.1). These results indicate that primed hepatic NK
cells develop and maintain an enhanced capacity for activation,
not just enhanced pathogen-specific recall. These results also
suggest that VV-specific memory NK cells may recognize
subsequent exposure to vaccinia virus through a combination of
signaling related to an induced self profile and direct recognition of
virally-encoded proteins. That we observed only small differences
in activation between NK cells stimulated with plate-bound
vaccinia virus and the unrelated virus adenovirus suggests that the
activation of NK cells is not driven predominantly by pathogen-
encoded antigens, although it remains a formal possibility that
formaldehyde fixation of the virus in these studies may have
diminished the capacity of NK cells to interact directly with and
recognize immunogenic portions of the virus.
We further sought to define a durable cell surface marker
expression profile acquired after a primary infection that might
identify a memory cell subpopulation within the liver-resident
Thy1
+ NK cell compartment. We observed significant increases in
total NK cell numbers in spleen (data not shown) and liver,
consistent with previous reports of global expansions of NK cell
populations after viral infections[7]. We also observed a
preferential expansion of the Thy1
+ NK cell population, as
determined both by the percentage and the absolute numbers of
Thy1
+ NK cells. Our EdU incorporation experiments (Fig. 5)
established that the expansion in total NK cell numbers, and
Thy1
+ NK cells in particular, is driven by in situ proliferation of
Thy1
+ NK cells during the first week of infection, not the
accumulation of effector cells migrating from peripheral sites. This
expansion of Thy1
+ NK cells was accompanied by a preferential
increase in the representation of a KLRG1
+ subset of cells that was
predominantly CD27
loCD11b
hiLy6c
hi(Fig. 4, b and c), a profile
consistent with these cells being mature, activated NK cell
effectors[24,25]. Importantly, in accordance with an earlier
report[7], we observed no preferential expansion of the Ly49H
+
NK cell subset that mediates innate memory against MCMV[2].
These data suggest that innate memory to vaccinia virus is
mediated by a subset of NK cells that is distinct from those that
form innate memory to MCMV. However, by 4 months post-
challenge, the phenotypic differences between the Thy1
+ liver NK
cell population in control and vaccinia virus-infected mice
observed during the acute phase of infection was no longer
apparent. This observation is consistent with a recent report that
previously stimulated NK cells retain enhanced functional capacity
in the absence of a phenotypic profile that distinguishes these cells
from naı ¨ve NK cells[26].
A significant concern that must be addressed when assessing the
protection against infection described in the present studies is
whether any residual functional T cell populations might be
present that would be capable of mediating the protection. In the
IgH
ko system, we were able to achieve extremely efficient
depletion of T cells as measured by anti-CD3 staining (approx-
imately 99% at 1 week post-challenge). However, while this T cell
depletion in the naı ¨ve and primed IgHko groups of mice was
efficient, complete depletion of all T cells was not possible. Despite
the fact that T cell depletion completely abrogated protection in
naı ¨ve IgH
ko recipients, it therefore remained a formal possibility
that residual T cells in the primed mice could contribute to host
protection. We therefore addressed this issue by adoptively
transferring highly purified NK cell subsets into naı ¨ve RAG1
ko
hosts and concurrently administering the same T cell-depleting
cocktail (Figs. 6-8; Fig. S3).
We were able to demonstrate that protection against vaccinia
virus could be transmitted to naı ¨ve RAG1
ko hosts by adoptive
transfer of purified vaccinia virus-primed Thy1
+ liver NK cells. Of
the naive RAG1
ko mice that received 1610
5 primed Thy1
+ liver
NK cells, 41% (9/22) were able to resolve a systemic, lethal
vaccinia virus challenge infection, while only 2% (1/49) of
RAG1
ko mice that received other purified NK cell subpopulations
were able to resolve and survive infection (Fig. 7). Our inability to
achieve protection in 100% of RAG1
ko mice by transfer of primed
Thy1
+ liver NK cells may be a consequence of limiting numbers of
Thy1
+ liver NK cells and the inefficiency associated with the cell
transfers.
We administered the T cell-depleting monoclonal antibody
cocktail to NK cell transfer recipients at the time of transfer to
prevent contaminating T cells from contributing to the protection
of these recipients. Indeed, as shown in Fig. 6,e v e nw h e n
transferring 20-fold more cells —cell preparations that contained
Figure 6. Protection conferred on naı ¨ve RAG1ko mice by adoptive transfer of primed lymphocytes is abrogated by simultaneous
administration of T cell-depleting monoclonal antibody cocktail. Groups of RAG1
ko mice received 2610
6 NK-depleted hepatic lymphocytes
from naı ¨ve or vaccinia virus-primed mice; a third group received both the primed lymphocytes and T cell-depleting monoclonal antibody cocktail
simultaneously. All groups were challenged with 1610
5 pfu rVV-luc ip 5 days later. (a) IVIS images of representative mice from the indicated recipient
groups are shown at various time points following challenge with rVV-luc. (b) The measurements of rVV-luc viral loads in each group over time are
shown, with relative viral loads based on the number of photons emitted, normalized for a 1 minute exposure. The measurement for each individual
mouse is plotted, and the mean is indicated by the centerline with error bars representing the SEM. Statistical analyses were performed using t tests
and Mann-Whitney analysis comparing the primed lymphocyte transferred & T-depleted group and the isotype-treated groups at various time points
to that of the naı ¨ve control group. Statistically significant differences between the depleted group and the isotype-treated groups post-challenge are
indicated by asterisks (p,0.05). Results are representative of 3 independent experiments.
doi:10.1371/journal.ppat.1002141.g006
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ko mice by the adoptive transfer
of primed Thy1
+ liver-resident NK cells. Six months after priming, 1610
5 Thy1
+ liver NK cells, 1610
5 Thy1
2 liver NK cells, or 5610
6 NK cell-
depleted liver mononuclear cells from vaccinia virus-primed or naı ¨ve mice were adoptively transferred into RAG1
ko mice. At the same time, mice were
administered either control immunoglobulins (those mice that received NK-depleted cell transfers) or T cell-depleting monoclonal antibodies (those
mice that received Thy1
- and Thy1
+ NK cell transfers). One week later the mice were challenged with 1610
5 pfu rVV-luc intraperitoneally, and viral
loads were monitored by IVIS imaging. (a) IVIS images of representative mice from each group over time following challenge are shown. (b) The
ability of RAG1
ko mice to resolve vaccinia virus infection by 3 weeks post-challenge is represented as the percent clearance within each group. Results
were compiled from 4 separate experiments. RAG1
ko mice that received primed Thy1
+ liver NK cells showed enhanced clearance of vaccinia virus as
compared to mice that received naı ¨ve Thy1
+ NK cells, naı ¨ve Thy1-depleted NK cells, and primed Thy1-depleted NK cells (two-tailed Fischer test
between groups). All statistics compare the test group relative to the group that received primed Thy1
+ liver-resident NK cells. (c) The ability of
RAG1
ko mice to clear vaccinia virus infection throughout the course of challenge is represented as the percent clearance within each group. Results
represent 4 separate experiments. RAG1
ko mice that received primed Thy1
+ liver NK cells showed enhanced protection against vaccinia virus
challenge as compared to mice that received naı ¨ve Thy1
+ NK cells, naı ¨ve Thy1
2 NK cells, and primed Thy1
2 NK cells. Statistical analysis was
performed to compare Kaplan-Meier survival curves using GraphPad Prism 4 software. All statistics compare the test group relative to the group that
received primed Thy1
+ liver-resident NK cells. Protection provided by transferred primed Thy1
+ hepatic NK cells surpassed the protection observed in
mice that received hepatic naı ¨ve Thy1
2 NK cells (using the log rank test; p=0.0168), primed Thy1
2 NK cells (p=0.0043), and naı ¨ve Thy1
+ NK
(p=0.0033). (d) Kaplan-Meier curves showing the survival of naı ¨ve RAG1
ko recipients of the indicated adoptively transferred cell populations. Results
represent the compilation of 4 separate experiments. RAG1
ko mice that received primed Thy1
+ liver NK cells showed enhanced survival of vaccinia
virus challenge as compared to mice that received naı ¨ve Thy1
+ NK cells, naı ¨ve Thy1
2 NK cells, or primed Thy1
2 NK cells. Statistical analysis was
performed as in (c), demonstrating that host protection provided by transferred primed Thy1
+ hepatic NK cells surpassed the protection observed in
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highly purified NK cell populations transferred in these
experiments — we observed that the T cell depleting cocktail
abolished protection (as measured by both IVIS and survival).
Further, when we looked for the presence of contaminating T
cells at d7, d14, and d28 post-challenge (d12, d19, and d33 post-
transfer and antibody administration, respectively), we were able
to identify transferred Thy1
+ NK cells but were unable to detect
T cells in the peripheral blood, livers, or spleens of NK cell
transfer recipients (Fig.8; Fig. S3). These data indicate that the
protection we observed in mice that received VV-primed Thy1
+
liver NK cell transfers was indeed conferred by this population of
cells (Figs. 7 and 8).
We also investigated whether MVA-primed Thy1
+ NK cells
from RAG1
ko hosts were capable of conferring the same
protection upon transfer into naı ¨ve immunodeficient hosts and
determined that priming with the highly attenuated MVA virus
was not sufficiently robust to generate protective memory
comparable to that induced by priming with live, replication
competent VV. There are several possible explanations for why
MVA priming did not engender the same degree of protective
innate memory. One possibility is that the viral product(s)
necessary for NK memory recognition of VV were lost in the
attenuation process. A recent study [3] was able to demonstrate
antigen-specific memory NK cells induced by a range of virus-like
particles (VLPs), including VLPs containing antigens derived from
pathogens not endemic to the mouse population (like HIV-1),
suggesting that this mechanism is unlikely. Even the highly
attenuated MVA strain has a rather large genome encoding an
extremely diverse range of potential antigens, including a wide
range of antigens shared with the vaccinia virus strain used in the
challenges. A second possibility is that NK memory formation to
VV requires conditioning from adaptive cell populations at some
point during the priming response. However, the ability of
RAG1
ko hosts to generate protective, pathogen-specific NK
memory upon exposure to a variety of VLPs also suggests that
the presence of classical adaptive lymphocytes are not necessary
during the priming phase for effective innate memory formation.
A third possibility is that, as has been observed for classical
memory [27], innate memory is generated more potently in
response to a live, replication-competent agent. If an ‘active’
infection stimulates a more robust response, it may do so is by
stimulating enhanced expression of self-molecules in cells under
the stress of active infection and replication. In such a scenario,
mice that received hepatic naı ¨ve Thy1
2 NK cells (log rank test; p=0.013), primed Thy1
2 NK cells (p=0.0049), or naı ¨ve Thy1
+ NK (p=0.0004). (e)
Kaplan-Meier curves showing the survival of naı ¨ve RAG1
ko recipients of the indicated adoptively transferred cell populations isolated from livers of
naı ¨ve and MVA-primed mice. RAG1
ko mice that received MVA-primed Thy1
+ liver NK cells showed no evidence of enhanced survival following rVV-luc
challenge as compared to mice that received naı ¨ve Thy1
+ NK cells, naı ¨ve Thy1
2 NK cells, or MVA-primed Thy1
2 NK cells. Statistical analysis was
performed as in (c and d). Results shown are representative of 2 independent experimental replicates.
doi:10.1371/journal.ppat.1002141.g007
Figure 8. Protected RAG1
ko hosts contain adoptively transferred Thy1
+ NK cells, not contaminating T lymphocytes. RAG1
ko mice
(CD45.2
+CD90.2
+) received transfers of 2610
6 NK cell-depleted mononuclear cells, or 1610
5 Thy1(CD90)
+ NK cells from livers of naı ¨ve or vaccinia
virus-primed B6.SJL mice (CD45.1
+CD90.2
+). Coincident with the transfers, mice received ip a mixture of isotype control (NK-depleted recipients) or T
cell-depleting (purified NK cell recipients) monoclonal antibodies. All recipients were challenged with 1610
5 pfu rVV-luc ip 5 days post-transfer.
Shown are representative results from individual animals at 7 days (a) or 14 days (b) post-challenge. Mice were imaged via IVIS analysis through the
course of the infection. At sacrifice, mononuclear cell suspensions were isolated from blood, spleens, and livers and analyzed via flow cytometry.
Ovaries were harvested in 10 mM Tris buffer pH 9.0 and snap frozen in a dry ice–ethanol bath prior to processing and evaluation using a standard
plaque formation assay on CV-1 cells. The recovered pfu/ovary are listed below each series of images (ND= none detected). Results are
representative of two independent experiments.
doi:10.1371/journal.ppat.1002141.g008
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respond to those stressed-self indicators through their array of
germline-encoded receptors.
These data demonstrate that VV infection generates a liver-
resident Thy1
+ NK cell population capable of mediating a
protective innate memory response. It is not clear how primed
Thy1
+ liver NK cells provide this protection against VV infection.
It will be important to determine whether innate memory NK cells
respond to pathogens more effectively than naı ¨ve memory NK
cells because they have enhanced lytic capacity, increased stores of
premade effector molecules (such as cytokines, granzyme, and/or
perforin), superior proliferative capacity, or an as yet undefined
property that facilitates a particularly robust effector response.
While the in vitro stimulation assay shown in this study indicates
that the primed NK cells do possess enhanced effector capacity
(Fig. 3), the precise mechanism by which this is mediated remains
unclear.
The mechanism by which primed Thy1
+ liver NK cells
recognize vaccinia virus upon secondary exposure is of great
importance. There are several hypotheses, not mutually exclusive,
that could account for pathogen-specific recognition of a
previously encountered pathogen. First, there may exist a whole
class of previously unidentified receptors expressed by innate cell
populations that, like Ly49H, have co-evolved to specifically
recognize the various pathogens endemic to the host population.
Such molecules could act as highly pathogen-specific pattern
recognition PRRs. Indeed, the murine homologue of the human
NKp46 receptor (also known as Ncr1) is critical for host defense
against influenza[28], and human NKp46 has been shown to bind
viral hemagglutinins[29,30,31]. Moreover, previous studies have
shown that genes within the NK complex on chromosome 6 in B6
mice contribute to NK cell-mediated immune responses to
ectromelia[32,33], an orthopoxvirus closely related to vaccinia
virus. This finding suggests that an as-yet-unidentified receptor
capable of recognizing a poxviral product may be encoded within
this region.
A second potential mechanism by which pathogen-specific
recognition could be mediated through germline-encoded recep-
tors could reflect alterations in the ability of NK receptors to
interact with MHC class I and MHC class I-like ligands when
binding and/or presenting viral epitopes. Alternatively, infection
by pathogen could induce a state within the cell that results in the
display of an ‘infected-self’- or ‘stressed-self’- associated profile of
protein expression that can then be recognized by receptors on
innate memory NK cells. One consequence of such an ‘infected-
self’ mechanism of recognition would be that the innate memory
formed in response to one pathogen might provide protection
against challenge with heterologous pathogens that induce a
similar molecular self-profile in infected cells. The phenomenon of
NK cell recognition and response to induced-self molecules has
previously been implicated in both infections and oncogene-
sis[34,35,36,37], where ligands MULT1[38], H60[39], and Rae-
1[39,40]) for the activating receptor NKG2D are preferentially
induced upon infection or cellular transformation[36,37,41].
Indeed, activation through NKG2D has been established as a
critical component of the NK cell response to ectromelia virus
infection[42]. That protective NK cell responses to poxvirus
infections have been tied to both an as-yet unidentified gene in the
B6 NK receptor complex[32,33] and to NKG2D activity[42]
suggests that both the pathogen-specific PRR and ‘infected-self’
mechanisms may contribute to NK cell responses to poxviruses.
Indeed, our in vitro assays showing enhanced responsiveness of
vaccinia virus-primed NK cells to stimulation through the NK1.1
receptor pathway as well as direct exposure to vaccinia virus would
be consistent with both mechanisms playing a significant role in
NK memory cell recognition of poxviruses.
These studies have established a model of innate memory to a
pathogen in a system in which there is no known pathogen-specific
receptor expressed by innate cell populations. This system will
allow us to explore models of innate memory recognition further.
Understanding the nature of that recognition will be critical for
harnessing innate memory for prophylactic or therapeutic use.
The stimulation of innate memory targeted to specific pathogens
might represent a novel and powerful approach for the design of
future vaccination strategies.
Materials and Methods
Ethics statement
This study was carried out in strict accordance with the
recommendations in the Guide for the Care and Use of
Laboratory Animals of the National Institutes of Health. All
animals are treated humanely and in accordance with the policies
of the Beth Israel Deaconess Medical Center (BIDMC), the
regulations of the Animal Welfare Act, and other laws and policies
of the federal government and other agencies. All mice were
maintained under specific-pathogen-free conditions and research
on mice was approved by the BIDMC Institutional Animal Care
and Use Committee (IACUC) under protocol #095-2009. All
efforts were made to minimize suffering of animals in this study.
Mice
Age-matched adult female C57Bl/6, B6.PL (Thy1.1 congenic),
B6.SJL (CD45.1 congenic), IgHm
ko (mMT[13,14]), and RAG1
ko
were obtained from Jackson Laboratories (Bar Harbor, ME). All
mice were maintained in the Harvard Institute of Medicine and
Beth Israel Deaconess Medical Center (BIDMC) Animal Research
facilities and used in accordance with protocols approved by the
Institutional Animal Care and Use Committees of BIDMC,
Harvard Institutes of Medicine, and Harvard Medical School.
Viruses
Stocks of recombinant vaccinia were prepared as previously
described[43]. Briefly, seed stocks of recombinant vaccinia virus
(Western Reserve strain) expressing firefly luciferase[44] (rVV-luc;
kindly provided by Michael Seaman (BIDMC; Boston, MA USA)
were added to HeLa cell monolayers at an MOI of 1. Seeded
monolayers were harvested and washed into 10 mM Tris pH 9.0
48–72 hours after seeding, and cell-associated virus was released
from cells by 3 freeze-thaw-sonication cycles followed by
centrifugation at 850 g for 10 min at 4uC. Supernatants
(containing free virus) were then layered over a 36% sucrose
cushion and centrifuged for 2 hours at 27,000 rpm (1.33610
5 g) at
4uC. After centrifugation, pellets containing purified cell-free virus
were resuspended in 10 mM Tris pH 9.0, aliquoted, and titered
using a standard in vitro plaque assay using CV-1 cells[43].
Recombinant Modified Vaccinia Ankara virus expressing firefly
luciferase [27] (rMVA-luc; were provided by Michael Seaman
(BIDMC; Boston, MA USA).
Antibodies for in vivo cell depletion
Sterile, certified low endotoxin preparations of monoclonal
antibodies H57–597 (hamster IgG anti-mouse TCRb)[16], UC7-
13D5 (hamster IgG3 anti-mouse TCRcd)[17], 30H12 (rat IgG2b
anti-mouse Thy1.2)[23], GK1.5 (rat IgG2b anti-mouse CD4)[15],
LTF-2 (rat IgG2b anti-Keyhole Limpet Hemagglutinin (KLH);
used as an isotype control), as well as a polyclonal preparation of
purified low endotoxin hamster IgG, were purchased from Bio-X-
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to the desired concentration, and administered intraperitoneally
(ip). Depleting or isotype control antibodies were administered
intraperitoneally to groups of naı ¨ve and VV-primed groups of
IgH
ko mice every 2 weeks starting at least 1 week prior to
secondary challenge. For adoptive transfer experiments, appro-
priate depleting or isotype control antibodies were administered
intraperitoneally concurrently with transfer of the indicated cell
populations.
Antibodies and secondary reagents for flow cytometric
analyses and cell sorting
Fluorescently conjugated antibodies specific for mouse CD3e
(clones 145-2C11, 17A2, and/or 500A2), CD11b (clone M1/70),
CD16/32 (clone 24G2; for blocking Fc receptor-mediated binding
of fluorescent labeled antibodies), CD49b (clone DX5), CD27
(clone LG.7F9), CD43 (clone eBioR2/60), CD45.1 (clone A20),
CD45.2 (clone 104), CD62L (clone MEL-14), CD69 (clone
H1.2F3), CD90.1 (clone HIS51), CD90.2 (clone 53-2.1), CD94
(clone 18d3), CD107a (clone 1D4B), CD107b (clone ABL-93),
CD127 (clone A7R34), CD244.2 (B6 2b4 alloantigen; clone
ebio244F4), KLRG1/MAFA (clone 2F1), Ly6c (clone AL-21)
Ly49C/I/F/H (clone 14B11), Ly49H (clone 3D10), NKG2D
(clone CX5), NK1.1 (clone PK136), TCRß (clone H57–597), and
TCRcd (clone GL-3) were obtained from either BD Biosciences
(San Jose, CA USA) or eBioscience, Inc. (San Diego, CA USA).
Isolation of cell populations
Livers were removed from naı ¨ve and vaccinia virus-primed B6,
B6.SJL (CD45.2 congenic), or B6.PL (CD90.1 congenic) mice and
diced in calcium-magnesium- free HBSS + 2% FBS prior to
enzymatic dissociation. Diced livers were resuspended in a digestion
buffer consisting of 500 mg/ml Collagenase D (.0.15 U/mg;
Roche Applied Science) and 10 mg/ml DNAse I (2500 U/mg;
Roche Applied Science) inHBSS + 2% FBS and agitated for1 hour
at 37uC. The resulting cell suspension was passed through a 70
micronfilterand added to the cell suspensionsreleased bydicingthe
livers harvested prior to digestion. The remaining pieces were
washed two additional times, and the resulting cell suspensions were
passed through a 70 micron filter and added to the previously
pooled cell suspensions. The pooled cell suspensions were then spun
at 500 g for 10 minutes at 20uC. The supernatant was discarded
and pelleted cells were resuspended and washed 2 more times in
HBSS + 2% FBS. The pelleted cells were then resuspended in 40%
Percoll in 1x HBSS, then underlaid with an equal volume of 67%
Percoll in 1x HBSS prior to centrifugation at 900 g for 30 minutes
at 20uC. Cells at the interface between the two Percoll layers were
saved and washed twice in MACS buffer (PBS +0.5% BSA
+2.5 mM EDTA). Cells for phenotypic analysis were counted using
Guava ExpressPlus software on a Guava easyCyte instrument
(Millipore; Billerica, MA) prior to staining with fluorescently-
conjugated monoclonal antibodies for analysis on an LSR II
instrument in our laboratory. For preparation of adoptive cell
transfers, two consecutive rounds of purification were performed:
first the mouse NK cell isolation kit (cat # 130-090-864) was used in
accordance with the manufacturer’s protocols (miltenyi biotec;
Bergisch Gladbach, Germany) to deplete non-NK cells on an
autoMACS instrument. The enriched NK population from B6 or
B6.SJL mice was then washed and separated via the AutoMACS
(program ‘possel’; non-labeled fraction is Thy1
2 NK, labeled
fraction is Thy1
+ NK) using MACS beads specific for CD90.2 (cat
# 130-049-101, miltenyi biotec). The enriched NK population
from B6.PL (CD90.1
+CD90.2
2) livers was incubated with antibod-
ies specific for CD3e, NK1.1, and Thy1.1 prior to flow cytometric
sorting into Thy1
2 NK (Thy1
2CD3
2NK1.1
+) and Thy1
+
(Thy1
+CD3
2NK1.1
+) populations on a BD Vantage instrument
in our laboratory.
Purified populations of NK cell-depleted blood mononuclear
cells (control; 2–5610
6 cells/mouse), Thy1
2 (1610
5 cells/mouse),
or Thy1
+ NK cells (1610
5 cells/mouse) in 1x PBS from naı ¨ve and
vaccinia virus-primed mice, or naı ¨ve RAG1
ko and MVA-primed
RAG1
ko mice, were transferred into age-matched female RAG1
ko
recipients via tail vein injection using a 25 G needle. Within 5 days
post-transfer, recipients were challenged with 1610
5 pfu of rVV-
luc ip and monitored over time using the IVIS Illumina-II imaging
system (Xenogen, inc.; Alameda, CA USA).
In vivo monitoring of viral burdens
At numerous time points following challenge, rVV-luc burdens
were monitored in vivo using the IVIS imaging system. Briefly, rVV-
luc –infected and/or uninfected control animals were injected ip
with 100 ml of a 30 mg/ml solution of firefly luciferin-D (Caliper
Life Sciences; Hopkinton, MA, USA) in PBS, and 100 mlo fa
20 mg/ml ketamine and 1.72 mg/ml xylazine mixture and imaged
14–16 minutes later in the IVIS series 100 imager (IgH
ko
experiments) or IVIS- lumina II instrument (adoptive transfer
experiments). Typical exposure times were 60 seconds (IVIS 100
series) or 30 seconds (IVIS-Lumina II); however, when higher viral
burdens were present exposure times were shortened to ensure that
images were not oversaturated, and all measurements were
normalized for one minute exposure. Overlay images and
luminescence measurements were made using Living Image
software (version 2.50.1; Xenogen).
In vitro stimulation assay
Tissue culture plates were treated with either carbonate binding
buffer alone (unstimulated and PMA/ionomycin wells), 1 mg/ml
control Ig (clone CI.8; Bio-X-cell) in binding buffer, 1 mg/ml anti-
NK1.1 (clone PK-136; Bio-X-cell), 2610
6 pfu/ml vaccinia virus, or
2610
6 vp adenovirus in binding buffer overnight at 4uC. Wells were
washed three times with HBSS + 2% FBS. Wells coated with
vaccinia virus or adenovirus were treated with 2% formaldehyde in
PBS for 20 minutes at room temperature, washed 4 additional times
with complete DMEM + 10% FBS, and all wells were blocked for
2h ra t4 uC with cDMEM + 10% FBS. 5610
5 liver mononuclear
cell preparations from groups of 8–12 mice were incubated in
DMEM alone (unstimulated, antibody coated, and vaccinia coated
wells) or DMEM with PMA and ionomycin (1 mg/ml and 5 mg/ml
respectively) for 6 hours at 37uC. Cell suspensions were then
recovered from the plate and processed for flow cytometric analysis.
In vivo proliferation assay
Groups of B6 mice were infected with 1610
7 pfu rVV ip
12 hours prior to sacrifice, infected mice and a matching group of
naı ¨ve mice were administered 250 mg of the thymidine analog 5-
ethynyl-29-deoxyuridine (EdU) in PBS ip. At sacrifice, mononu-
clear cells were isolated from livers and spleens, stained with
monoclonal antibodies to NK1.1, CD3e, CD90.2, and fixed. Fixed
cells were then washed in a permeabilization buffer containing
saponin, treated with Click-IT EdU staining buffer containing
Alexa 647 azide to stain incorporated EdU, washed, and analyzed
by flow cytometry.
Vaccinia CV-1 plaque assay
Ovaries were harvested in 10 mM Tris pH 9.0 and snap frozen
on a dry ice-ethanol bath. Samples were then thawed, homoge-
nized, and snap frozen again. The samples were then thawed,
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cDMEM + 10% FCS. 500 ml of each dilution was placed on a
confluent layer of CV-1 cells in 6 well plates and incubated at
37uC for one hour, prior to aspiration and addition of 3 ml
cDMEM + 10%FCS to each well. Plates were incubated for an
additional 48 hours at 37uC prior to aspiration and staining and
fixing with 500 ml of 0.1% crystal violet in 20% ethanol for 5 min.
After removing the staining solution, the plates were air-dried and
then counted. Viral loads in the ovaries were calculated based on
the number of plaques, the dilution factor, and the volume of
homogenate.
Supporting Information
Figure S1 Representative IgH
ko priming data. Adult
IgH
ko mice received 1610
7 pfu rVV-luc intraperitoneally and
were monitored over time by IVIS imaging. Mice were rested a
minimum of 6 months after initial clearance of the rVV-luc prior
to use in challenge experiments.
(TIF)
Figure S2 Representative IVIS imaging and ovarian pfu
recovered from vaccinia virus-challenged IgHko mice.
IVIS imaging is shown of the viral load and distribution in
individual IgHko mice throughout the course of the experiment.
Unless otherwise noted, mice were sacrificed approximately 5
weeks after challenge. At the time of sacrifice, ovaries were
harvested in 10 mM Tris buffer pH 9.0 and snap frozen in a dry
ice–ethanol bath prior to processing and evaluation using a
standard plaque formation assay on CV-1 cells. The recovered
pfu/ovary are listed to the right of each series of images (ND=
none detected).
(TIF)
Figure S3 NK cells transferred into RAG1
ko hosts
persist and do not contain contaminating T lymphocytes
at 4 weeks post-challenge. RAG1
ko mice received transfers of
5610
6 NK cell-depleted mononuclear cells, 1610
5 Thy1
2 NK
cells, or 1610
5 Thy1
+ NK cells from livers of naı ¨ve or vaccinia
virus-primed wild type mice. Coincident with the transfers, mice
received ip a mixture of isotype control (NK-depleted recipients) or
T cell-depleting (purified NK cell recipients) monoclonal antibod-
ies. All recipients were challenged with 1610
5 pfu rVV-luc ip 5
days post-transfer. (a) Shown are representative flow cytometric
analyses of viable mononuclear cells from the peripheral blood (all
recipients) and spleens (NK cell recipients only) 28 days post-
challenge. (b) Flow cytometric plots of cell populations in
RAG1ko hosts (CD90.2
+) that received adoptive transfers of
vaccinia virus-primed B6.PL Thy1(CD90.1)
+ NK cells 4 weeks
post-challenge by staining cell suspensions from livers and spleens
For CD3, NK1.1, CD90.1, and CD90.2. The left panels are gated
on total lymphocytes and show the absence of contaminating T
cells (CD3
+CD90.1
+). Middle panels are gated on total lympho-
cytes and show the NK cell (CD3
2NK1.1
+) population and
corresponding NK cell gate. The right panel are plots showing
events within the NK cell gate shown in the middle panel, and
show the presence of transferred Thy1(CD90)
+ B6.PL NK cells
[CD3
2NK1.1
+CD90.1
+] within the host NK cell population (host
Thy1(CD90)
+NK are CD90.2
+).
(TIF)
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